Skip to content
Review Open access

Histone deacetylases in cancer metabolic reprogramming

Sep 2026 · Experimental and Molecular Medicine · Vol 58, pp. 2812 - 2824 · 1 citation · 102 references
Medicine

TL;DR

It is suggested that developing isoform-specific HDAC inhibitors could enhance therapeutic precision, particularly in targeting cancer’s metabolic dependencies, pointing towards future research directions in cancer metabolism and epigenetics.

Abstract

Cancer cells undergo extensive metabolic reprogramming to sustain rapid proliferation and adapt to heterogeneous tumour microenvironments. These metabolic alterations are tightly linked to epigenetic regulation, which reshapes gene expression and cellular signalling mechanisms. Among epigenetic regulators, histone deacetylases (HDACs) have emerged as key modulators of cancer metabolic reprogramming. Along with their canonical roles in histone deacetylation, HDACs regulate non-histone substrates, including metabolic enzymes and transcription factors, thereby coordinating transcriptional and metabolic programmes. In this review, we summarize current insights into HDAC-mediated regulation of glucose, lipid and amino acid metabolism in cancer and discuss the metabolic mechanisms underlying the anticancer effects of HDAC inhibitors. Collectively, we propose an integrated framework in which HDACs function as central regulators of cancer metabolic reprogramming. We highlight the limitations of HDAC inhibitor studies and discuss the emerging importance of isoform-specific HDAC functions in reprogramming cancer-specific metabolic dependencies and therapeutic strategies. Histone deacetylases (HDACs) are crucial in epigenetic regulation, influencing gene expression and cellular metabolism. This review explores the roles of HDACs in cancer metabolic reprogramming, particularly in glucose, lipid and amino acid metabolism. The authors discuss how HDACs, through deacetylation, regulate both histone and non-histone proteins, impacting processes such as glycolysis, the Warburg effect and fatty-acid oxidation. They highlight significant findings, such as the role of HDAC1 in controlling glucose and lipid metabolisms and the regulation of glycolysis and glutamine metabolism in cancer by HDAC6. These insights underscore the potential of HDACs as therapeutic targets, with HDAC inhibitors already in clinical use for cancer treatment. The review suggests that developing isoform-specific HDAC inhibitors could enhance therapeutic precision, particularly in targeting cancer’s metabolic dependencies, pointing towards future research directions in cancer metabolism and epigenetics. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.

Read PDF

Similar papers

Review Open access Oct 2026

Histone Lactylation in Cancer: Linking Hypoxia-Driven Metabolism to Epigenetic Regulation

Solid tumors are frequently characterized by hypoxia, which drives metabolic reprogramming toward glycolysis and increased lactate production. Beyond its role as a metabolic end product, lactate can influence gene regulation through histone lactylation, a recently identified post-translational modification linking cell...

Julia Ostapowicz, K. Kulcenty · 0 citations
Review Open access Sep 2026

The Crosstalk Between Metabolic Reprogramming and Histone Methylation in Tumor Immunity and Immunotherapy

Histone methylation regulates chromatin structure and gene expression, whereas tumor metabolism provides bioenergetic and biosynthetic inputs. These processes are bidirectionally linked: S-adenosylmethionine supplies methyl groups for histone methyltransferases, α-ketoglutarate(α-KG) supports JmjC-domain demethylases,...

Jia-Yao Dou, Rui-Cheng Xue, Wei Gao et al. · 0 citations
Review Open access Oct 2026

Lysine lactylation in glioma: from metabolic stress to epigenetic remodeling and therapeutic resistance

This review systematically summarizes current progress on the lactate-Kla axis in glioma, encompassing the basis of lactate metabolism, the molecular regulatory network of Kla, and the distinct yet coordinated functions of histone and non-histone lactylation.

Xiao-Song Hu, Li Yang, Yang-Hao Hu et al. · 0 citations
Editorial Open access Oct 2026

Epigenetics in cancer: from mechanisms to precision medicine

This Thematic Issue on Epigenetics in Cancer brings together leading experts to review recent conceptual and technological advances that are reshaping the field and highlights how fundamental discoveries are driving translational innovation and precision oncology.

Sung Hee Baek · 0 citations
Review Open access Sep 2026

HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges

Histone deacetylases (HDACs) are key regulators of chromatin architecture and gene expression, and their dysregulation is closely linked to tumorigenesis, making them attractive targets for cancer therapy. Histone deacetylase inhibitors (HDACis) exert broad antitumor effects by modulating both epigenetic and non-epigen...

Kun Liu, Xiang Zhao, Jia-Hui Liu et al. · 0 citations
Review Open access Sep 2026

Cancer Metabolism: Recent Advances in Biochemical Mechanisms and Targeted Therapeutic Strategies

Background: Cancer is characterized not only by genetic and epigenetic abnormalities but also by profound alterations in cellular metabolism. Metabolic reprogramming enables malignant cells to meet the increased requirements for energy production, biosynthesis, redox regulation, proliferation, invasion, and adaptation...

Arshiya Fatima, Mohammed Abdul Muqeeth, K. Maanasa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.